Eye – Talk Bio

FDA Advisory Committee Votes Against GSK’s Blenrep in Multiple Myeloma

6 days ago talkbio0Tagged Advisory Committees, Clinical Trials, drug safety, Eye, Multiple Myeloma, ODAC, SmithKline Beecham, Toxicity aspects, United States Food and Drug Administration, vote

FDA Advisory Committee; Blenrep; GSK; multiple myeloma; ODAC vote; drug safety; ocular toxicity; clinical trials

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

1 week ago talkbio0Tagged Advisory Committees, Blenrep, Drug Approval, Eye, Eye safety, Multiple Myeloma, relapsed/refractory multiple myeloma, SmithKline Beecham, Toxicity aspects, United States, United States Food and Drug Administration

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma

Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus

7 months ago talkbio0Tagged BRIMOCHOL, Eye, fluorouracil/melphalan, Phase 3 trial, presbyopia, Tenpoint Therapeutics, vision drug, Visus merger

Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics

AOA’s ‘Eye Deserve More’ Campaign Highlights the Unmatched Capabilities of the Human Eye

11 months ago talkbio0Tagged Americas Ethnicity, Blindness, Comprehensive Eye Care, Digital Eye Strain, Eye, Eye Deserve, Homo sapiens, Optometric Association, Optometry, The Eye

American Optometric Association, Eye Deserve More, The Eye, Human Eye, Eye Health, Comprehensive Eye Care, Digital Eye Strain, Vision Loss, Optometry

Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study

11 months ago talkbio0Tagged Discomfort, Dry Eye Syndromes, Eye, Phase 3 Clinical Trials, Rejection (Psychology), reproxalap, United States Food and Drug Administration

Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection